Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Shares Outstanding (Weighted Average) (2016 - 2026)

Ovid Therapeutics filings provide 11 years of Shares Outstanding (Weighted Average) readings, the most recent being $136.2 million for Q1 2026.

  • Quarterly Shares Outstanding (Weighted Average) rose 10893611.44% to $136.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $136.2 million through Mar 2026, up 10893611.44% year-over-year, with the annual reading at $1171.0 for FY2025, 100.0% down from the prior year.
  • Shares Outstanding (Weighted Average) hit $136.2 million in Q1 2026 for Ovid Therapeutics, up from $67.3 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $136.2 million in Q1 2026 and bottomed at $1250.0 in Q1 2024.
  • Average Shares Outstanding (Weighted Average) over 5 years is $53.5 million, with a median of $70.4 million recorded in 2022.
  • The largest annual shift saw Shares Outstanding (Weighted Average) crashed 100.0% in 2025 before it soared 10893611.44% in 2026.
  • Ovid Therapeutics' Shares Outstanding (Weighted Average) stood at $70.4 million in 2022, then increased by 0.22% to $70.6 million in 2023, then rose by 0.46% to $70.9 million in 2024, then dropped by 5.03% to $67.3 million in 2025, then skyrocketed by 102.21% to $136.2 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's Shares Outstanding (Weighted Average) are $136.2 million (Q1 2026), $67.3 million (Q4 2025), and $1250.0 (Q3 2025).